Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2025 07:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially...
February 20, 2025 09:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate...
February 13, 2025 16:30 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor...
February 04, 2025 07:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor...
January 06, 2025 16:59 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor...
January 02, 2025 07:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor...
November 25, 2024 07:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Participation in Upcoming December Conferences

AUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor...
November 14, 2024 07:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash balance of approximately $90M as of September 30,...
October 01, 2024 06:30 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest...
August 01, 2024 16:05 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights

– Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS)...